Alteration of sequence of a target molecule

Details Alteration of sequence of a target molecule Alteration of sequence of a target molecule

2006-05-16

2006-05-16

Fredman, Jeffrey (Department: 1637)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S005000, C435S091100, C514S04400A, C536S023100, C536S024100, C536S024500, C536S025100

Reexamination Certificate

active

07045293

ABSTRACT:
Method for splicing a target nucleic acid molecule with a separate nucleic acid molecule. Such splicing generally causes production of a chimeric protein with advantageous features over that protein naturally produced from the target nucleic acid prior to splicing. The method includes contacting the target nucleic acid molecule with a catalytic nucleic acid molecule including the separate nucleic acid molecule. Such contacting is performed under conditions in which at least a portion of the separate nucleic acid molecule is spliced with at least a portion of the target nucleic acid molecule to form a chimeric nucleic acid molecule. In this method, the catalytic nucleic molecule is chosen so that it is not naturally associated with the separate nucleic acid molecule.

REFERENCES:
patent: 4987071 (1991-01-01), Cech et al.
patent: 5126260 (1992-06-01), Tuan et al.
patent: 5225337 (1993-07-01), Robertson
patent: 5389514 (1995-02-01), Taylor
patent: 5498531 (1996-03-01), Jarrell
patent: 5641673 (1997-06-01), Haseloff et al.
patent: 5667969 (1997-09-01), Sullenger
patent: 5869254 (1999-02-01), Sullenger
patent: 6897016 (2005-05-01), Sullenger et al.
patent: 90/01731 (1990-05-01), None
patent: 88/04300 (1988-06-01), None
patent: 92/07065 (1992-08-01), None
patent: 92/13089 (1992-08-01), None
patent: 92/13090 (1992-08-01), None
patent: 93/00833 (1993-05-01), None
Goyette et al (Mol. Cell. Biol. (1992) 12(3):1387-1395).
Weber et al., “Antiviral properties of a dominant negative mutant of the herpes simplex virus type 1 regulatory protein ICP0,”Journal of General Virology73:2955-2961 (1992).
Rossi, “Controlled, targeted, intracellular expression of ribozymes: progress and problems,”TIBTECH13:301-306 (1995).
Komatsu et al., “Cross-ligation and exchange reactions catalyzed by hairpin ribozymes,”Nucleic Acids Research21:185-190 (1993).
Friedman et al., “Expression of a truncated viraltrans-activator selectively impedes lytic infection by its cognate virus,”Nature335:452-454 (1988).
Flanegan and Cech, “Tetrahymena Ribozyme Catalyzes Trans-splicing of Model Oligoribonucleotide Substrates,” J. Cell. Biochem, 12D, Apr. 4, 1998, New York, p. 28.
Cech, “The Chemistry of Self-Splicing RNA and RNA Enzymes,”Science236:1532-1539 (1987).
Sullenger and Cech, “Ribozyme-mediated repair of defective mRNA by targeted trans-splicing,”Nature371:619-622 (1994).
Guthrie, “Messenger RNA Splicing in Yeast: Clues to Why the Spliceosome Is a Ribonucleoprotein,”Science253:157-163 (1991).
Kim and Cech, “Three-dimensional model of the active site of the self-splicing rRNA precursor ofTetrahymena,”Proc. Natl. Acad. Sci. USA84:8788-8792 (1987).
Haseloff and Gerlach, “Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities,”Nature334:585-591 (1988).
Cech, “Ribozymes and Their Medical Implications,”JAMA260:3030-3034 (1988).
Jeffries and Symons, “A Catalytic 13-mer Ribozyme,”Nucleic Acids Research17:1371-1377 (1989) (also referred to as Jefferies).
Rossi et al., “Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems,”Aids Research and Human Retroviruses8:183-189 (1992).
Hampel and Tritz, “RNA Catalytic Properties of the Minimum (-)sTRSV Sequence,”Biochemistry28:4929-4933 (1989).
Hampel et al., “Hairpin' Catalytic RNA Model: Evidence for Helices and Sequence Requirement for Substrate RNA,”Nucleic Acids Research18:299-304 (1990).
Perrotta and Been, “Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis δ Virus RNA Sequence,”Biochemistry31:16-21 (1992).
Guerrier-Takada et al., “The RNA Moiety of Ribonuclease P Is the Catalytic Subunit of the Enzyme,”Cell35:849-857 (1983).
Inoue et al., “Intermolecular Exon Ligation of the rRNA Precursor of Tetrahymena: Oligonucleotides Can Function as a 5′ Exons,”Cell43:431-437 (1985).
Bruzik et al., “Spliced leader RNAs from Lower eukaryotes aretrans-spliced in mammalian cells,”Letters to Nature360:692-695 (1992).
Cech et al., “In VitroSplicing of the Ribosomal RNA Precursor of Tetrahymena: Involvement of a Guanosine Nucleotide in the Excision of the Intervening Sequence,”Cell27:487-496 (1981).
Kruger et al., “Self-Splicing RNA: Autoexcision and Autocyclization of the Ribosomal RNA Intervening Sequence of Tetrahymena,”Cell31:147-157 (1982).
Rossi, “Controlled, targeted, intracellular expression of ribozymes: progress and problems,”TIBTECH13:301-306 (1995).
Been and Cech, “One Binding Site Determines Sequence Specificity of Tetrahymena Pre-rRNA Self-Splicing, Trans-Splicing, Trans-Splicing and RNA Enzyme Activity,”Cell47:207-216 (1986).
Cech, “Ribozyme Engineering,”Current Opinion in Structural Biology2:605-609 (1992).
Dzierzak et al., “Lineage-specific Expression of a Human β-globin Gene in Murine Bone Marrow Transplant Recipients Reconstituted with Retrovirus-Transduced Stem Cells,”Nature331:35-41 (1989).
Konarska et al., “TransSplicing of mRNA Precursors in Vitro,”Cell42:165-171 (1985).
Kruger et al., “Self-Splicing RNA: Autoexcision and Autocyclization of the Ribosomal RNA Intervening Sequence of Tetrahymena,”Cell31:147-157 (1982),.
Malim et al., “Functional Dissection of the HIV-1 RevTrans-Activator—Derivation of aTrans-Dominant Repressor of Rev Function”Cell58:205-214 (1989).
Morgan and Anderson, “Human Gene Therapy,”Annu. Rev. Biochem. 62:191-217 (1993).
Murphy and Cech, “Alteration of Substrate Specificity for the Endoribonucleolytic Cleavage of RNA by theTetrahymenaRibozyme,”Proc. Natl. Acad. Sci. USA86:9218-9222 (1989).
Price and Cech, “Coupling ofTetrahymenaRibosomal RNA Splicing to β-Galactosidase Expression inEscherichia coli,”Science228:719-722 (1985).
Price and Cech, “Determinants of the 3′ Splice Site for Self-splicing of theTetrahymenapre-rRNA,”Genes&Development2:1439-1447 (1988).
Sarver et al., “Ribozymes as Potential Anti-HIV-1 Therapeutic Agents”Science247:1222-1225 (1990).
Smith et al., “Development of alacZMarked WEHI-3B D+Murine Leukemic Cell Line as anIn-VivoModel of Acute Non-Lymphocytic Leukemia,”Leukemia7:310-317 (1993).
Solnick, “TransSplicing on mRNA Precursors,”Cell42:157-164 (1985).
Sullenger et al., “Overexpression of TAR Sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication,”Cell63:601-608 (1990).
Trono et al., “HIV-1 Gag Mutants Can Dominantly Interfere with the Replication of the Wild-type Virus,”Cell59:113-120 (1989).
Tsuchihashi et al., “Protein Enhancement of Hammerhead Ribozyme Catalysis,”Science262:99-102 (1993).
van der Veen et al., “Excised Group II Introns in Yeast Mitochondria are Lariats and Can Be Formed by Self-splicing In Vitro,”Cell44:225-234 (1986).
Waring et al., “The Tetrahymena rRNA Intron Self-Splices in E. Coli: In Vivo Evidence for the Importance of Key Base-Paired Regions of RNA for RNA Enzyme Function,”Cell40:371-380 (1985).
Weber et al., “Antiviral properties of a dominant negative mutant of the herpes simplex virus type 1 regulatory protein ICP0,”Journal of General Virology73:2955-2961 (1992).
Zaug and Cech, “The Intervening Sequence RNA ofTetrahymenaIs a Enzyme,”Science231:470-475 (1986).
Zaug et al., “TheTetrahymenaRibozyme Acts Like an RNA Restriction Endonuclease,”Nature324:429-433 (1986).

Affiliated with

Also associated with

Rating

Alteration of sequence of a target molecule does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Alteration of sequence of a target molecule, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alteration of sequence of a target molecule will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3571302